๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Delhi
Clinical trial register · India

Clinical Trials in New Delhi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 40 Bangalore 39 New Delhi 38 Mumbai 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Liver and Biliary Sciences, India46 AstraZeneca38 Novartis Pharmaceuticals22 Bristol-Myers Squibb18 Eli Lilly and Company17 Clear sponsor filter
Site location
Kolkata54 Delhi40 Bangalore39 New Delhi38 Mumbai37
All 76 locations
Target enrolment
to
38 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
AstraZeneca
Phase 3
600
Ahmedabad, Bangalore, Gurgaon, Kottayam, Madurai, Nashik, New Delhi, Vadodara
2026-09-29
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Kolkata, Kottayam, Nashik, Navi Mumbai, New Delhi
2026-07-16
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mohali, Mumbai, New Delhi, Varanasi
2026-02-03
Recruiting
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
NCT06531798Moderate to Severe COPD
AstraZeneca
Phase 4
150
Dalgate, Drugjan, Hyderabad, Lucknow, Nagpur, New Delhi
2026-01-30
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Bangalore, Kolkata, Mumbai, Nashik, New Delhi
2025-10-31
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
AstraZeneca
Phase 3
3,103
Belagavi, Dehradun, Kanpur, Kochi, New Delhi
2025-05-28
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Active, closed
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
NCT06429761BREAST CANCER
AstraZeneca
Phase 4
100
Bangalore, Delhi, Kochi, Mumbai, New Delhi, Pune, Varanasi
2025-01-02
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 3
594
Ahmedabad, Hyderabad, Mumbai, New Delhi
2024-03-04
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Bangalore, Calicut, Kanpur, Kolkata, Nagpur, New Delhi, Pune, Vadodara
2023-11-21
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Ahmedabad, Delhi, Gurugram, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Bangalore, Belagavi, Delhi, Nadiฤd, New Delhi
2023-11-07
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
AstraZeneca
Phase 3
800
Calicut, Jaipur, Lucknow, Madurai, Mohali, Nagpur, Nashik, New Delhi
2023-09-22
Active, closed
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110Lung Malignancy
AstraZeneca
Observational
712
Gurugram, New Delhi, Hyderabad, Bangalore, Chennai, Kolkata, Mumbai, Pune
2023-04-20
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
Bangalore, Jaipur, Kolkata, Nagpur, Nashik, New Delhi, Puducherry, Vadodara
2022-05-16
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Bikaner, Meerut, Mohali, New Delhi
2022-03-25
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Gurgaon, Howrah, Nagpur, Nashik, New Delhi, Raipur, Rishikesh, Surat
2021-10-25
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
AstraZeneca
Phase 3
366
Gurgaon, Jaipur, Kolkata, Madurai, Namakkal, Nashik, New Delhi
2021-05-31
Rows per page Showing 1–25 of 38
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india/city/new-delhi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.